Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.8K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.8K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.0K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?

Blood cancer journal·2019
Same author

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.

Nature communications·2019
Same author

Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia.

Clinical lymphoma, myeloma & leukemia·2019
Same author

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience.

Journal of hematology & oncology·2019
Same author

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial.

The Lancet. Haematology·2018
Same author

Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice.

Advances in experimental medicine and biology·2018

Related Experiment Video

Updated: Dec 31, 2025

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.4K

Myeloid sarcoma.

Omar A Shahin1, Farhad Ravandi

  • 1Department of Leukemia, University of Texas - MD Anderson Cancer Center, Houston, Texas, USA.

Current Opinion in Hematology
|January 7, 2020
PubMed
Summary
This summary is machine-generated.

Myeloid sarcoma, a rare disease often linked to acute myeloid leukemia (AML), requires molecular and cytogenetic analysis for effective treatment. Management involves AML-type chemotherapy, with postremission therapy tailored to individual patient risk.

More Related Videos

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

10.0K
Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.5K

Related Experiment Videos

Last Updated: Dec 31, 2025

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.4K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

10.0K
Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.5K

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Myeloid sarcoma, also known as granulocytic sarcoma or chloroma, is a rare extramedullary tumor.
  • It frequently co-occurs with acute myeloid leukemia (AML) but can arise independently.

Purpose of the Study:

  • To review current literature on myeloid sarcoma.
  • To focus on treatment strategies for this rare condition.
  • To evaluate the prognostic and therapeutic significance of molecular and cytogenetic aberrations.

Main Methods:

  • Literature review of recent studies on myeloid sarcoma.
  • Analysis of diagnostic, prognostic, and therapeutic approaches.
  • Assessment of molecular and cytogenetic testing in myeloid sarcoma management.

Main Results:

  • Molecular and cytogenetic testing are crucial adjuncts to conventional diagnostics.
  • Testing for targetable mutations in myeloid sarcoma cells is feasible and guides treatment.
  • Outcomes depend on the disease's background, with most patients progressing to AML.
  • Standard care involves AML-type chemotherapy for remission induction; postremission therapy (SCT, radiotherapy, consolidation chemotherapy) is risk-dependent.

Conclusions:

  • Further research is needed to elucidate the nature of myeloid sarcoma.
  • Inclusion of myeloid sarcoma patients in clinical trials is recommended.
  • Improved diagnostic, prognostic, and therapeutic strategies require further investigation.